What did @richgaspari actually say?
The short version: Gaspari says BPC-157 and TB-500 were "taken off the market not because they're dangerous because they work," and that he switched to pentadecapeptide arginate (PDA), injected it into his knee for two weeks, and his pain resolved. He's now plugging a specific pharmacy and clinic in Las Vegas owned by a former training partner.
To his credit, he's transparent about the commercial relationship. He names the person, names the business, and says "a good friend of mine." That's more disclosure than most influencer peptide posts offer. But transparency about a conflict of interest doesn't make the medical claims accurate. Let's go through them.
Does the science back this up?
For BPC-157, there's genuine preclinical signal. The evidence for PDA is thinner and newer, which matters a lot here.
BPC-157 (Body Protection Compound-157) has a real research base, mostly in rodent models. Studies including Sikiric et al. (2018, Current Pharmaceutical Design) have documented accelerated tendon, ligament, and muscle healing in animal models. The problem is that robust human clinical trial data remains scarce. What works in a rat tendon doesn't automatically transfer to a human knee.
TB-500, a synthetic fragment of thymosin beta-4, has similarly promising animal data and very limited human evidence.
Pentadecapeptide arginate is newer and has even less published research. It's structurally related to BPC-157, differing in its arginine salt form. Proponents argue this improves stability and oral/injectable bioavailability, but peer-reviewed comparative pharmacokinetic data in humans is essentially nonexistent at this point. Gaspari calling it "very similar to BPC-157" is plausible at a molecular level but gets well ahead of the clinical evidence.
What did they get wrong (or right)?
The "taken off the market because they work" line is the biggest problem in this video. It's a conspiracy framing that isn't supported by the regulatory record.
The FDA's 2023 action placing BPC-157 and TB-500 on its list of bulk drug substances that cannot be compounded was based on a determination that these substances lack adequate evidence of safety and effectiveness for use in compounded preparations, and that they present potential safety risks. You can disagree with that regulatory judgment. Plenty of researchers do. But "big pharma wants to make money off them" is not the documented reason. The FDA's own notices cite insufficient safety data, not commercial suppression. Gaspari is presenting a motivated narrative as established fact.
What he got right: his description of these as peptides used for inflammation and recovery is accurate category-level framing. And his acknowledgment that he "tweaked" his knee rather than claiming a serious injury was healed is appropriately modest compared to some peptide content online.
What should you actually know?
If you're considering any of these peptides, the regulatory and safety picture is genuinely complicated, and Gaspari's video doesn't give you the information you need to make an informed decision.
First, compounded peptides are not FDA-approved drugs. Quality, purity, and sterility can vary significantly between compounding pharmacies. Injecting a compound of uncertain purity into a joint is not a trivial risk.
Second, "injecting it into the area" the way Gaspari describes is not equivalent to a clinically supervised intra-articular injection. Site-specific injection of peptides requires sterile technique and anatomical precision that a self-administered insulin needle approach does not guarantee.
Third, anecdote is not data. Gaspari is a 61-year-old elite-level former bodybuilder describing a two-week subjective experience with no control condition. His knee feeling better could reflect the peptide, rest, time, placebo effect, or a combination. We cannot know from this video.
If you want to explore peptide therapy for recovery, that conversation belongs with a licensed provider who can review your full health picture, not a clinic referral from an Instagram post.